Recombinant human GHRH(1-44)NH2: clinical utility and therapeutic development program

Area of Science:

• Endocrinology
• Geriatrics
• Pharmacology

Background:

• Growth hormone (GH) secretagogues are emerging as alternatives to GH or insulin-like growth factor-I (IGF-I) therapy.
• They stimulate endogenous GH release, preserve feedback control, and avoid adverse effects associated with GH treatment in the elderly.
• Growth hormone-releasing hormone (GHRH) is well-characterized for its pituitary somatotropic activity.

Purpose of the Study:

• To evaluate the efficacy and tolerability of chronic subcutaneous growth hormone-releasing hormone (GHRH) administration in elderly subjects.
• To investigate GHRH's potential therapeutic applications in conditions prevalent in the elderly.

Main Methods:

• Early phase clinical trials are assessing GHRH efficacy and tolerability.
• Studies involve chronic subcutaneous administration of GHRH across various doses.
• Participants are elderly individuals with conditions such as congestive heart failure and osteoporosis.

Main Results:

• Growth hormone-releasing hormone (GHRH) is being evaluated for its potential benefits.
• The studies aim to establish optimal dosing and assess safety in the elderly population.
• Potential therapeutic areas include congestive heart failure, osteoporosis, and improving body composition and function in frail elderly individuals.

Conclusions:

• Growth hormone-releasing hormone (GHRH) shows potential as a therapeutic agent for the elderly.
• Further clinical trials are necessary to confirm efficacy and tolerability for specific conditions.
• GHRH represents a novel approach to activating the GH/IGF-I axis in aging populations.